CU6 10.1% $6.13 clarity pharmaceuticals ltd

CU6 - Media and Industry News, page-293

  1. 72 Posts.
    lightbulb Created with Sketch. 15
    Clarity will have superior prostate imaging products, I have no doubt and potentially prostrate therapy to a degree, but I think there will be different use cases for therapy’s as the market is so large.
    TLX isn't a one trick pony, they have about 10 products targeting different cancers eg. TLX kidney imaging product awaiting approval has sensitivity of 86% which is quite high for an imagining product, and I don’t believe it will be superseded in a hurry.
    Last edited by njpet8: Yesterday, 16:56
 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.